Literature DB >> 32040811

Quality of Care Among Medicare Patients Undergoing Pancreatic Surgery: Safety Grade, Magnet Recognition, and Leapfrog Minimum Volume Standards-Which Quality Benchmark Matters?

Katiuscha Merath1, Rittal Mehta1, Diamantis I Tsilimigras1, Ayesha Farooq1, Kota Sahara1, Anghela Z Paredes1, Lu Wu1, Amika Moro1, Aslam Ejaz1, Mary Dillhoff1, Jordan Cloyd1, Allan Tsung1, Timothy M Pawlik2.   

Abstract

BACKGROUND: The association of national quality benchmarking metrics with postoperative outcomes following complex surgery remains unknown. We assessed the relationship between the "quality trifactor" of Leapfrog minimum volume standards, Hospital Safety Grade A, and Magnet Recognition with outcomes of Medicare patients undergoing pancreatectomy.
METHODS: The Standard Analytic Files (SAF) merged with Leapfrog Hospital Survey and Leapfrog Safety Scores Denominator Files were reviewed to identify Medicare patients who underwent pancreatic procedures between 2013 and 2015. Primary outcomes were overall and serious complications, as well as 30- and 90-day mortality. Multivariable logistic regression analyses were conducted to evaluate possible associations among hospitals meeting the quality trifactor and short-term outcomes.
RESULTS: Among 4853 Medicare patients, 909 (18.7%) underwent pancreatectomy at hospitals meeting the quality trifactor. Among 260 hospitals, 7.3% (n = 19) met the quality trifactor. Safety Grade A (48.8%, n = 127) was the most commonly met criterion followed by Magnet Recognition (36.2%, n = 94); the Leapfrog minimum volume standards were achieved by 25% (n = 65) of hospitals. Patients undergoing surgery at hospitals that were only Safety Grade A and Magnet designated, but did not meet Leapfrog criteria, had higher odds of serious complications (OR 1.59, 95% CI 1.00-2.51). In contrast, patients undergoing treatment at hospitals having all three designations (i.e., the quality trifactor) had 40% and 39% lower odds of both serious complications (OR 0.60, 95% CI 0.37-0.97) and 90-day mortality (OR 0.61, 95% CI 0.42-0.89), respectively. In turn, patients undergoing pancreatectomy at quality trifactor hospitals had higher odds of experiencing the composite quality measure textbook outcome (OR 1.28, 95% CI 1.03-1.59) versus patients undergoing pancreatectomy at non-trifactor hospitals.
CONCLUSION: While Safety Grade A and Magnet designation alone were not associated with higher odds of an optimal composite outcome following pancreatectomy, compliance with Leapfrog criteria to achieve the "quality trifactor" metric was associated with lower odds of serious complications and mortality.

Entities:  

Keywords:  Leapfrog; Magnet Recognition; Pancreas; Pancreatectomy; Quality of care

Mesh:

Year:  2020        PMID: 32040811     DOI: 10.1007/s11605-019-04504-6

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  2 in total

1.  Using administrative data to screen hospitals for high complication rates.

Authors:  L I Iezzoni; J Daley; T Heeren; S M Foley; J S Hughes; E S Fisher; C C Duncan; G A Coffman
Journal:  Inquiry       Date:  1994       Impact factor: 1.730

2.  Association between Leapfrog safe practices score and hospital mortality in major surgery.

Authors:  Feng Qian; Stewart J Lustik; Carol A Diachun; Richard N Wissler; Raymond A Zollo; Laurent G Glance
Journal:  Med Care       Date:  2011-12       Impact factor: 2.983

  2 in total
  2 in total

1.  A machine learning risk model based on preoperative computed tomography scan to predict postoperative outcomes after pancreatoduodenectomy.

Authors:  Giovanni Capretti; Cristiana Bonifacio; Crescenzo De Palma; Martina Nebbia; Caterina Giannitto; Pierandrea Cancian; Maria Elena Laino; Luca Balzarini; Nickolas Papanikolaou; Victor Savevski; Alessandro Zerbi
Journal:  Updates Surg       Date:  2021-10-01

2.  Textbook outcomes in hepatobiliary and pancreatic surgery.

Authors:  Diamantis I Tsilimigras; Timothy Michael Pawlik; Dimitrios Moris
Journal:  World J Gastroenterol       Date:  2021-04-21       Impact factor: 5.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.